Education
About Us
Working with TipRanks
Follow Us
Amylyx Pharmaceuticals Inc (AMLX)
NASDAQ:AMLX
AMLX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.58 - $7.27
Previous CloseN/A
Volume98.90K
Average Volume (3M)800.88K
Market Cap
$310.99M
Enterprise Value-$11.21M
Total Cash (Recent Filing)$77.39M
Total Debt (Recent Filing)$1.98M
Price to Earnings (P/E)―
Beta1.62
Next Earnings
May 08, 2025EPS Estimate
-0.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.43
Shares Outstanding88,602,470
10 Day Avg. Volume800,316
30 Day Avg. Volume800,876
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.70
Price to Cash Flow (P/CF)-1.40
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.04
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.25
Enterprise Value/Ebitda0.04
Forecast
1Y Price Target
$8.67Price Target Upside152.77% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
---
Amylyx Pharmaceuticals Inc News
PremiumCompany Announcements
Amylyx Pharmaceuticals Reports 2024 Financial Results
PremiumCompany Announcements
Amylyx Pharmaceuticals’ Earnings Call Highlights Clinical Progress
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessAvexitide showed superior efficacy in reducing hypoglycemic events across different dosing regimens.
Financial StabilityAmylyx has sufficient cash into 2026 despite a net loss in 3Q25, providing a financial cushion for ongoing developments.
Regulatory ProgressAmylyx has reached an agreement with the FDA on a phase 3 primary endpoint for avexitide, with plans to initiate a randomized placebo-controlled phase 3 trial.
Bears Say
Financial PerformanceAmylyx ended 4Q24 with ~$177M of cash, which the company believes, in addition to $66M raised in Jan, should provide cash runway into the end of 2026.
Pipeline ChallengesThe rest of Amylyx's pipeline beyond avexitide is viewed as having a relatively low probability of approval and is considered as upside for valuation.
---
Ownership Overview
14.16% Insiders
5.40% Mutual Funds
26.93% Other Institutional Investors
47.53% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AMLX FAQ
What was Amylyx Pharmaceuticals Inc’s price range in the past 12 months?
Amylyx Pharmaceuticals Inc lowest stock price was $1.57 and its highest was $7.27 in the past 12 months.
What is Amylyx Pharmaceuticals Inc’s market cap?
Amylyx Pharmaceuticals Inc’s market cap is $310.99M.
When is Amylyx Pharmaceuticals Inc’s upcoming earnings report date?
Amylyx Pharmaceuticals Inc’s upcoming earnings report date is May 08, 2025 which is in 33 days.
How were Amylyx Pharmaceuticals Inc’s earnings last quarter?
Amylyx Pharmaceuticals Inc released its earnings results on Mar 04, 2025. The company reported -$0.55 earnings per share for the quarter, missing the consensus estimate of -$0.52 by -$0.03.
Is Amylyx Pharmaceuticals Inc overvalued?
According to Wall Street analysts Amylyx Pharmaceuticals Inc’s price is currently Undervalued.
Does Amylyx Pharmaceuticals Inc pay dividends?
Amylyx Pharmaceuticals Inc does not currently pay dividends.
What is Amylyx Pharmaceuticals Inc’s EPS estimate?
Amylyx Pharmaceuticals Inc’s EPS estimate is -0.5.
How many shares outstanding does Amylyx Pharmaceuticals Inc have?
Amylyx Pharmaceuticals Inc has 88,602,470 shares outstanding.
What happened to Amylyx Pharmaceuticals Inc’s price movement after its last earnings report?
Amylyx Pharmaceuticals Inc reported an EPS of -$0.55 in its last earnings report, missing expectations of -$0.52. Following the earnings report the stock price went up 0.333%.
Which hedge fund is a major shareholder of Amylyx Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in AMLX
---
Amylyx Pharmaceuticals Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.67 (152.77% Upside)
$8.67 (152.77% Upside)
Blogger Sentiment
Bullish
AMLX Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 2.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $426.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 8.8%
Last 30 Days ▼ 8.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
33.46%
12-Months-Change
Fundamentals
Return on Equity
-100.88%
Trailing 12-Months
Asset Growth
-62.58%
Trailing 12-Months
Company Description
Amylyx Pharmaceuticals Inc
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
---
AMLX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook with significant advancements in clinical trials and a strong financial position. However, there are challenges related to operational cash use and the inherent risks in clinical and regulatory processes.Read More>---
AMLX Stock 12 Month Forecast
Average Price Target
$8.67
▲(152.77% Upside)
Technical Analysis
Best Analysts Covering AMLX
1 Year
1 Year Success Rate
7/18 ratings generated profit
1 Year Average Return
-20.42%
reiterated a buy rating last month
Copying Andrew Fein's trades and holding each position for 1 Year would result in 38.89% of your transactions generating a profit, with an average return of -20.42% per trade.
---